Sandoz Forms Insulin Biosimilars Deal With Gan & Lee
Executive Summary
In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.
You may also be interested in...
Sandoz And Ares Extend AMR Collaboration Ahead Of Next Phase
With plans to enable genomic surveillance for antimicrobial resistant pathogens using Ares’ next-generation sequencing and bioinformatics technologies, the OpGen subsidiary and Sandoz have shaken hands on an extension to their initial master services agreement.
Sandoz Partner Gan & Lee Wraps Phase III Insulin Glargine Trial
Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).
Gan & Lee Insulins Data Is Boon For Sandoz
Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.